Benzinga

Benzinga

Benzinga

miércoles, agosto 26

Monte Rosa Therapeutics Inc

GLUENASDAQ
Trade with Public
Trade with Public
$14.30
-0.26-1.75%
Últ. Act.: Aug 26, 1:23 PM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Monte Rosa Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Monte Rosa Therapeutics (GLUE).

Price Target Range — 10 Quarters

Analyst Consensus — 6 Analysts

6Buy
Consensus RatingOverweight# Analysts6Avg. Consensus PT$25Upside to Avg. PT+75.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 25, 2026GuggenheimMichael SchmidtMaintainedBuy$28
Aug 7, 2026JP MorganBrian ChengPT CutOverweight$31→$27
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target

Guggenheim analyst Michael Schmidt reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $28 price target.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $31 to $27.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28

Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and lowers the price target from $35 to $28.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $29 to $27.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Monte Rosa Therapeutics, Lowers Price Target to $27

Wedbush analyst Robert Driscoll maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and lowers the price target from $37 to $27.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35

Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and raises the price target from $30 to $35.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved